Gábor Oroszlán
Senior Manager, Miniprotein Platform VRG Therapeutics
Gabor Oroszlan, currently Senior Manager of Miniprotein Platform at VRG Tx, is a Harvard-trained scientist with expertise in structural biology and protein engineering. He leads a cross-functional team developing VRG’s drug discovery platform, AI-MPRO, while also overseeing early-stage pipeline projects. He is responsible for advancing programs from project initiation through in silico–to–in vitro translation, and to early in vivo proof of concept.
Seminars
Wednesday 26th August 2026
Tackling Challenging Mechanisms of Action with De Novo Miniproteins
12:30 pm
- Developing an end-to-end AI-MPRO platform to design miniprotein therapeutics against challenging targets, including ion channels and complex multi-protein interfaces that are difficult to address with conventional modalities
- Combining de novo protein design with rapid in silico experimental iteration, enables efficient progression from computational discovery to in vitro and in vivo preclinical proof-of-concept
- Generating compact, highly optimized miniprotein candidates with the potential to deliver first-in-class or best-in-class therapies for targets traditionally considered intractable
